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ABSTRACT 33 
Background: Neutrophil extracellular traps (NETs) have been observed in the airway in 34 
COPD, but their clinical and pathophysiological implications have not been defined. 35 
Objective: To determine if NETs are associated with disease severity in COPD, and how they 36 
are associated with microbiota composition and airway neutrophil function. 37 
Methods: NET protein complexes (DNA-Elastase and Histone-Elastase complexes), cell free 38 
DNA and neutrophil biomarkers were quantified in soluble sputum and serum from COPD 39 
patients during periods of disease stability and during exacerbations, and compared to 40 
clinical measures of disease severity and sputum microbiome. Peripheral blood and airway 41 
neutrophil function was evaluated by flow cytometry ex vivo and experimentally following 42 
stimulation of NET formation. 43 
Results: Sputum NET complexes were associated with the severity of COPD evaluated using 44 
the composite GOLD scale (p<0.0001). This relationship was due to modest correlations 45 
between NET complexes and FEV1, symptoms evaluated by the COPD assessment test and 46 
higher levels of NET complexes in patients with frequent exacerbations (p=0.002). 47 
Microbiota composition was heterogeneous, but there was a correlation between NET 48 
complexes and both microbiota diversity (P=0.009) and dominance of Haemophilus spp 49 
operational taxonomic units. (P=0.01). Ex vivo airway neutrophil phagocytosis of bacteria 50 
was reduced in patients with elevated sputum NET complexes. Consistent results were 51 
observed regardless of the method of quantifying sputum NETs. Failure of phagocytosis 52 
could be induced experimentally by incubating healthy control neutrophils with COPD 53 
soluble sputum. 54 
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Conclusion: NET formation is increased in severe COPD and is associated with more frequent 55 
exacerbations and a loss of microbiota diversity. 56 
Abstract word count: 250 57 
Key messages:  58 
• Neutrophil extracellular traps (NETs) have been observed in the lungs of patients 59 
with chronic obstructive pulmonary disease; their significance in terms of clinical 60 
outcomes and their impact on bacterial clearance in the airway has not been 61 
established. 62 
• We show that NETS in sputum are associated with loss of microbiota diversity and 63 
impaired ex vivo neutrophil phagocytosis suggesting a possible role in disease 64 
progression. 65 
• Consistent with this, measurement of NETs in sputum identifies patients with worse 66 
lung function, poorer quality of life and a higher risk of future exacerbations. 67 
Capsule summary: Neutrophil extracellular traps are associated with disease severity and 68 
loss of microbiota diversity in COPD, suggesting a role in disease pathogenesis and 69 
progression. 70 
Keywords: Neutrophils, phagocytosis, COPD, Haemophilus, exacerbations  71 
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Abbreviations: 72 
ACE Angiotensin converting enzyme 
ARB Angiotensin receptor blocker 
BAL Bronchoalveolar lavage 
BMI Body mass index 
BSA Bovine serum albumin 
CABG Coronary artery bypass graft 
CAT COPD assessment test 
CCF Congestive cardiac failure 
cfDNA Cell-free Deoxyribonucleic acid 
COPD Chronic obstructive pulmonary disease 
CRP C-reactive protien 
DNA Deoxyribonucleic acid 
DPI Diphenyleneiodonium 
ELISA Enzyme linked immunosorbent assay 
FEV1 Forced expiratory volume in 1 second 
FITC Fluorescein isothiocyanate 
FVC Forced vital capacity 
GOLD Global initiative for obstructive lung disease 
HRCT High resolution computed tomography scan 
HRP Horseradish peroxidase 
ICS Inhaled corticosteroids 
LABA Long acting beta agonist 
LAMA Long acting muscarinic antagonist 
LPS Lipopolysaccharide 
LTOT Long term oxygen therapy 
MPO Myeloperoxidase 
MRC Medical research council 
NET Neutrophil extracellular trap 
OTU Operational taxonomic unit 
PMA Phorbol 12-myristate 13-acetate 
QIIME Quantitative insights in microbial ecology 
ROC Receiver operating characteristic 
SGRQ St. Georges respiratory questionnaire 
StDev Standard deviation 
SWDI Shannon-Wiener species diversity index 
TARDIS Tayside Allergy and Respiratory Disease Information System 
TMB 3,3’5,5’-Tetramethylbenzidine 
  73 
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INTRODUCTION 74 
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disorder, primarily 75 
caused by cigarette smoking, with multiple phenotypes and an unpredictable clinical course; 76 
drivers of disease progression remain poorly understood (1-4). Aberrant neutrophilic 77 
inflammation is characteristic of COPD, and neutrophils contribute to airway damage 78 
through the release of proteases and reactive oxygen species (5), leading to loss of alveoli, 79 
increased mucus production, and mucociliary dysfunction. Normally, activated neutrophils 80 
rapidly undergo apoptosis and are removed by alveolar macrophages in a non-inflammatory 81 
manner; this process is essential in resolving inflammation and preventing disease 82 
progression; neutrophil phagocytosis is therefore a crucial defence against bacterial 83 
infection but also important in resolving inflammation and limiting disease progression in 84 
COPD (6-8). Cigarette smoke directly promotes neutrophilic inflammation but also impairs 85 
this antibacterial defence, leading to disturbance of the resident microbiota which, in turn, 86 
promotes neutrophil influx and exacerbates inflammation (9, 10). 87 
An alternative method of neutrophil antimicrobial defence, called neutrophil extracellular 88 
trap formation or NETosis has been described (11). This is an extracellular method of 89 
pathogen trapping in which neutrophils extrude webs of de-condensed chromatin studded 90 
with histones, neutrophil elastase and other granule products that ensnare bacteria. While 91 
the ability of NETs to ensnare target microorganisms is not in doubt, their direct role in 92 
bacterial killing remains controversial (11, 12). The cellular mechanisms that mediate lytic 93 
NET formation are still to be elucidated, but evidence is accumulating that neutrophil 94 
elastase plays a central role, initially translocating from cytoplasmic granules to the nucleus, 95 
where it instigates chromatin degradation through histone cleavage (13). 96 
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NETs have recently been identified in the sputum of small numbers of stable and 97 
exacerbating COPD patients through the use of confocal fluorescent and electron 98 
microscopy (14-16). In Grabcanovic-Musija et al (14), COPD disease severity, as measured by 99 
lung function, was associated with a greater amount of NET-associated neutrophil elastase 100 
determined by confocal laser microscopy. However, the clinical and pathophysiological 101 
relevance of NETs in COPD has not been established. In this study we used multiple methods 102 
to evaluate airway NET release and correlated them with clinical disease severity, the airway 103 
microbiome and neutrophil function. We demonstrate that NETs are more abundant in 104 
severe COPD, and are associated with more frequent exacerbations, reduced microbiota 105 
diversity and abundance of Haemophilus species.  106 
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METHODS 107 
COPD patients enrolled in a community COPD registry (Tayside Allergy and Respiratory 108 
Disease Information System (TARDIS) (17, 18) were recruited into this prospective 109 
longitudinal cohort study. Patients were included if >40 years; a FEV1/FVC ratio <70% and 110 
with a clinical diagnosis of COPD. Exclusion criteria included the inability to give informed 111 
consent; previous adverse reaction to nebulised hypertonic saline; asthma; bronchiectasis 112 
on HRCT scanning; cystic fibrosis; active mycobacterial disease; and immunosuppression. 113 
Patients receiving long term antibiotic therapy or maintenance oral corticosteroid therapy at 114 
screening were also excluded. Study approval was granted by the East of Scotland Research 115 
Ethics Committee (13/ES/0030); all patients gave written informed consent to participate. 116 
Study Design 117 
Patients underwent a comprehensive clinical assessment and sampling of blood and sputum 118 
at two time points up to 6 months apart whilst clinically stable. Exacerbations were reported 119 
to the research team who provided standardized treatment with repeat clinical assessment, 120 
blood and sputum sampling at the onset of exacerbation and at day 10 after treatment. 121 
Exacerbations were defined as previously described (19). Relevant medical history was 122 
recorded at screening (see online supplement for details). Sputum was obtained following 123 
nebulisation of 3% hypertonic saline for up to 20 mins. Spirometry, St Georges Respiratory 124 
Questionnaire (SGRQ), COPD assessment test (CAT) and MRC dyspnoea scoring was 125 
performed at each visit. The primary outcome was the association between NET complexes 126 
and composite GOLD COPD severity classification. This classifies patients into four groups, A, 127 
B, C and D depending on their symptoms (CAT score and MRC dyspnoea score), lung function 128 
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(FEV1 % predicted) and exacerbation frequency (high risk defined as 2 or more per year or a 129 
hospitalisation for a severe exacerbation) (20).  130 
NET Assays 131 
There is no agreed high throughput method of quantifying NETs in biological fluids, 132 
consequently, this study utilised multiple methods. Firstly, primary NET constituents 133 
including cell free DNA (cfDNA), Myeloperoxidase and neutrophil elastase and EN-RAGE, 134 
were quantified (21). These assays are not specific as these components are also released 135 
during neutrophil degranulation or necrosis but are commonly used as surrogates of NET 136 
release. Subsequently, three specific methods of NET quantification were used: A MPO-DNA 137 
ELISA that has been extensively published (21-23) and two assays developed and validated in 138 
house for use in sputum, based on the detection of DNA-Elastase and Histone-Elastase 139 
complexes. For the DNA-Elastase complex assay, Anti-DNA (HYB331-01, Abcam) capture 140 
antibody, was incubated on plates overnight at 4°C, following by washing with PBS + 0.05% 141 
Tween 20 (wash buffer). Plates were blocked with 1% Bovine Serum Albumin (BSA) in PBS 142 
and washed with wash buffer. Samples were diluted in 1% BSA in PBS. A standard curve was 143 
generated by titrating concentrations of heathy human blood-derived neutrophils treated 144 
with phorbol 12-myristate 13-acetate (PMA). Plates were washed 3 times with wash buffer 145 
after incubation of standards and samples. DNA-elastase complexes were detected with 146 
sheep anti-neutrophil elastase-HRP (PA1-74133, Thermo Scientific) and developed with 147 
3,3’5,5’-Tetramethylbenzidine (TMB). For the Histone-Elastase assay, plates were coated for 148 
1h with Anti-Histone H1 (ab71594, Abcam), washed and blocked as above, and incubated for 149 
1h with Rabbit anti-neutrophil elastase (ab21595, Abcam). Anti-Rabbit-HRP (ab6721, Abcam) 150 
was used for detection and the plate was developed as above. The assays were validated 151 
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against other known NET components (citrullinated histone H3 and DNA) for the effects of 152 
sample preparation methods and for passive interactions between DNA and elastase 153 
(Figures E1-E3 online). 154 
Sputum Microbiome 155 
DNA was extracted from whole sputum using the AllPrep DNA/RNA Mini kit on the QIAcube 156 
automation platform (QIAGEN) using a modified protocol, followed by 16S rRNA gene 157 
sequencing on the Illumina MiSeq platform. Bioinformatic analysis and quality checking of 158 
the resulting sequences was performed using QIIME (version 1.9.0) (24). Shannon-Wiener 159 
Species Diversity Index (SWDI) was used as a measure of alpha diversity of samples.  See 160 
online supplement for full methods. 161 
Neutrophil studies 162 
Peripheral blood neutrophils were isolated by percoll-gradient density centrifugation as 163 
previously described (6). Phagocytosis by peripheral blood and airway neutrophils was 164 
assessed using a flow cytometry based assay (25); see online supplement. Sputum 165 
neutrophil platelet aggregates were investigated by flow cytometry, while cytospins were 166 
obtained for differential sputum cell counts; see online supplement. 167 
Statistical Analysis 168 
Details of all statistical analyses carried out are shown in the online supplement. 169 
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RESULTS 170 
99 patients were included in the study. Patient characteristicsare shown in Table 1. 171 
NETs are associated with clinical disease severity in stable COPD 172 
Sputum NETs were measured on expectorated sputum from all individuals. NETs quantified 173 
using the Histone-Elastase complex assay were associated with multiple markers of COPD 174 
severity. Sputum NETS were highest in those in 2011 GOLD group B and D, the most severe 175 
groups using this composite index of COPD severity c(consisting of lung function (%predicted 176 
FEV1), symptoms (MRC dyspnoea and CAT score) and exacerbation frequency), (Figure 1A, 177 
P<0.0001). (26) We explored the individual contributors to the GOLD classification and found 178 
that Sputum NETs were also independently correlated with annual exacerbation frequency 179 
(Figure 1B, P=0.002),  % predicted FEV1 (Figure 1C, P<0.0001and CAT score (Figure 1D, 180 
P=0.005),, Patients hospitalised with severe exacerbations also had higher sputum NETs, 181 
P=0.002). Very similar results were obtained with the DNA-elastase assay (Figure E4 online). 182 
The MPO-DNA assay had a limited dynamic range and was not considered further.  183 
Soluble sputum NET concentrations were not correlated with age, smoking pack years, BMI 184 
or use of the anti-platelet agents aspirin or clopidogrel using any assay. In multivariable 185 
analysis, sputum NETs were independently associated with % predicted FEV1 in multiple 186 
linear regression (estimate -0.19, per 100 unit change in NET concentration, P=0.03). 187 
Histone-elastase levels were also independently associated with % predicted FEV1 (p=0.01). 188 
Sputum NET concentrations using both DNA-elastase and Histone-elastase assays correlated 189 
with sputum neutrophils identified on cytospins (P<0.0001), sputum EN-RAGE (P<0.0001), 190 
cfDNA (P<0.0001), MPO (P<0.0001) and neutrophil elastase (P<0.0001). These results 191 
indicate that the abundance of NETs in sputum correlate with disease severity. To determine 192 
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if this was simply a reflection of systemic inflammation, the quantity of NETs in sputum were 193 
compared with the concurrent presence of NETs in peripheral blood. Circulating DNA-194 
elastase concentrations were on average 10,000 fold lower than in sputum, and did not 195 
correlate with any markers of disease severity (data not shown).  196 
To determine whether sputum NET concentration could be used as a predictive biomarker, 197 
we used ROC analysis. This showed the optimal cut-off to identify frequently exacerbating 198 
patients (>2 per year) was >0.98units/mL DNA-elastase complexes. Using this cut-off, 199 
sputum NET concentration predicted time to next exacerbation (P<0.0001) by Kaplan-Meier 200 
survival analysis. Similarly, using a cut-off of >0.34 units/mL Histone-elastase complexes 201 
predicted time to next exacerbation (P<0.0001). In multivariable analysis, DNA-elastase and 202 
Histone-elastase complexes were associated with exacerbation frequency even after 203 
adjustment for confounders: (1.03 95% CI 1.01-1.06, per 0.1 unit increase, P=0.02 and 1.04 204 
(95% CI 1.02-1.07 per 0.1 unit increase, P=0.007 respectively). Included confounders were 205 
age, gender, smoking status, BMI, FEV1% predicted, MRC dyspnoea score and use of inhaled 206 
corticosteroids (ICS). 207 
Other sputum markers of severity 208 
cfDNA was not associated with exacerbation frequency or GOLD score but was associated 209 
with sputum colour (Table E1 online). Other NET markers, including elastase, MPO and EN-210 
RAGE were associated with severity markers including exacerbations, % predicted FEV1 and 211 
GOLD score, but generally the relationships were weaker for these non-specific assays than 212 
for the NET assays (Figure 2 and Table E1 online). Neutrophil elastase activity was associated 213 
with GOLD stage but not significantly with exacerbations. 214 
Sputum NET concentration is associated with microbiota composition  215 
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Results of 16S rRNA sequencing of DNA from whole sputum from stable and exacerbating 216 
COPD patients is shown in Figures 3 and 4 respectively. The SWDI was used as a 217 
measurement of the richness and evenness of the bacteria population found in the sputum; 218 
a lower index indicates fewer species and more un-evenness within a sample. Increasing 219 
sputum NET concentration was associated with a decreasing SWDI in stable patients using 220 
both DNA-elastase and Histone-elastase assays (Figure 3). In patients with stable disease and 221 
also during exacerbations, Haemophilus was most frequently the dominant pathogenic 222 
genus in patients with reduced species diversity. When stratified by the presence of >40% 223 
Haemophilus spp. OTUs at genus level (based on Figure E5 online), there was a clear 224 
relationship between Haemophilus spp dominance and NET formation as measured by 225 
Histone-elastase complexes P<0.0001 and DNA-elastase complexes P=0.01 (Figure 3C).  226 
We investigated microbiota dynamics over the study period to determine if antibiotic 227 
therapy may be responsible for reductions in SWDI or Haemophilus spp. dysbiosis. 228 
Comparing patients who did and did not received antibiotic therapy during 6 months follow-229 
up there were no significant differences in change in SWDI, Chao index or % of Haemophilus 230 
spp. OTU’s (Figure E6 online). High variability in NET concentration between Baseline and 231 
Follow-up was observed but this was not statistically significant (Figure E7 online). 232 
Neutrophil extracellular traps during exacerbations of COPD 233 
63 exacerbations requiring antibiotic and corticosteroid treatment occurred during the study 234 
period in 39 patients. We studied a convenience sample of 24 exacerbations where patients 235 
could be reviewed and sampled prior to administration of treatment. We quantified NETs in 236 
induced sputum at onset and after treatment of exacerbation. (Figure 4A). Exacerbations 237 
were heterogeneous with microbiota profiling demonstrating some exacerbations were 238 
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associated with loss of bacterial diversity while others showed no change overall microbiota 239 
profile (Figure 4B). There was an association between DNA-elastase complexes and SWDI 240 
during exacerbations (R=0.48, P=0.02). There was a significant association between sputum 241 
NETs and severity of exacerbation as measured by CAT (R=0.35, P=0.005) and SGRQ (R=0.25, 242 
P=0.01). Similar results were observed with the Histone-elastase assay. NETs were 243 
significantly elevated in exacerbations where Haemophilus spp. was dominant (P=0.01 for 244 
DNA-elastase and P=0.0005 for histone-elastase, Figure 4C). Classifying exacerbations as 245 
eosinophilic or non-eosinophilic, as described by Bafadhel et al (27); there was a clear excess 246 
of NETs in sputum in non-eosinophilic exacerbations compared with low levels during 247 
eosinophilic exacerbations (Figure 4D, P=0.01 for both assays), consistent with the premise 248 
that the underlying pathologic disease process in these exacerbations may be different. 249 
Investigating potential mechanisms of NET formation in COPD implicates failure of 250 
phagocytosis 251 
We investigated a number of recognised NET triggers of relevance to COPD such as CXCL8 252 
(28), complement component C5a, bacterial infection (described above) and activated 253 
platelets (23). We observed no relationship between sputum CXCL8 and NETs (Figure 5C). 254 
Complement component C5a was not detectable in the majority of sputum samples by ELISA 255 
(data not shown). Markers of platelet activation were significantly elevated in COPD sera 256 
(CD40L, (Figure 5B) and P-selectin); analysis of sputum by flow cytometry showed the 257 
presence of neutrophil-platelet aggregates (Figure 5A), but we found no evidence of a 258 
correlation between the degree of platelet activation and NET formation (correlation 259 
between NETs and CD41a positive neutrophils, P=0.053). A sub-analysis in patients with and 260 
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without treatment with anti-platelet drugs confirmed these findings. Similar results were 261 
observed with the Histone-elastase assay (not shown). 262 
Branzk et al demonstrated that NET formation in bacterial infection only occurred when 263 
phagocytosis was inhibited (29). The phagocytic capacity of neutrophils, monocytes and 264 
alveolar macrophages in COPD have been extensively studied (30), and there is abundant 265 
evidence that phagocytosis is compromised in this disease. We therefore evaluated airway 266 
neutrophil phagocytosis of FITC labelled P. aeruginosa to test the hypothesis that impaired 267 
phagocytosis in the presence of airway bacteria may contribute to NET formation. We 268 
observed a failure of neutrophil phagocytosis in patients with high sputum DNA-elastase 269 
complex concentrations (Figure 6B, P=0.002 and P=0.007). Near identical results were 270 
obtained using the histone-elastase assay (Figure E8 online). The relationships between 271 
cfDNA, free sputum CXCL8, IL-1beta, TNF-alpha and EN-RAGE and phagocytosis were not 272 
statistically significant.  273 
We excluded an effect of neutrophil viability on phagocytosis by demonstrating no 274 
correlation between caspase positive cells and phagocytosis. We also observed a correlation 275 
between NET formation and daily beclomethasone dose equivalent of ICS. The relationship 276 
was explained by a higher level of NET formation in patients receiving fluticasone 277 
propionate/salmeterol (P=0.01, Figure E9 online). In vitro, we found that fluticasone 278 
propionate at therapeutically relevant doses inhibited neutrophil phagocytosis of FITC-279 
labelled E. coli (Figure 6C), and that pooled sputa from COPD patients similarly reduced 280 
phagocytosis (this pool was formed of patients not receiving ICS to exclude the possibility of 281 
inhaled drug in the samples affecting neutrophil function). To test the hypothesis that 282 
neutrophil products released into the sputum were responsible for phagocytosis inhibition 283 
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we treated blood neutrophils with PMA for 4 hours to induce NET formation and harvested 284 
the supernatant. This supernatant also demonstrated a dose dependent inhibition of 285 
neutrophil phagocytosis after 30 mins incubation (a time point too early for NET formation in 286 
response to PMA to have occurred). The positive control, cytochalasin D, inhibited 287 
phagocytosis as expected.  288 
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DISCUSSION  289 
This study shows NET formation is present in COPD, and that NET concentrations are 290 
associated with disease severity in COPD, with higher levels of NET complexes in patients 291 
with more severe disease when classified by the composite GOLD severity score which 292 
incorporates % predicted FEV1, symptoms and the frequency of exacerbations.During 293 
exacerbations, elevated NETs were associated with non-eosinophilic exacerbations and 294 
reduced bacterial diversity, driven by increased Haemophilus species. 295 
NETs therefore appear to be potential biomarkers of disease severity and microbial dysbiosis 296 
in COPD. Further work is required to address whether NETs directly contribute to disease 297 
progression in COPD or are a reflection of more severe lung damage and associated 298 
alterations in the microbiota.  299 
Neutrophil killing is critical to defence against bacterial and fungal pathogens in the lung.  It 300 
is now known that neutrophils are able to alter their killing method, for example by sensing 301 
pathogen size and releasing NETs in response to large pathogens (29). The killing method 302 
appears to be binary, as Branzk et al (29) showed that NET formation was inhibited by 303 
phagocytosis through sequestration of neutrophil elastase, which is required to translocate 304 
to the nucleus to initiate NET formation (29, 31). In vivo evidence of this dichotomous 305 
neutrophil behaviour has not previously been shown during human infections.  306 
Microscopy studies have now demonstrated the presence of NETs in the airways of patients 307 
with cystic fibrosis, COPD and asthma (14-16, 32, 33). The questions are therefore not 308 
whether NETs are present, but whether they are important in the progression of the disease 309 
and what drives NET formation in the COPD airway? 310 
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The number of recognised triggers for NET formation in in vitro systems is vast, and includes 311 
pro-inflammatory cytokines (CXCL-8, TNF-alpha), bacterial products (formylated peptides, 312 
LPS), bacteria (P. aeruginosa, H. influenzae), fungi, activated platelets and rheumatoid factor 313 
(immunoglobulin) (11, 23, 29, 31, 33-36). Evaluating the drivers of NET formation in COPD is 314 
challenging since the majority of these proposed drivers are present in the COPD airway 315 
under normal conditions (5). In this study NETs were most strongly correlated, during both 316 
stable COPD and exacerbations, with the presence of Haemophilus spp. OTUs. Juneau 317 
previously demonstrated that H. influenzae were able to induce NETs directly, and it has 318 
been shown that H. influenzae may survive in NETs through the production of nucleases and 319 
resistance to NET killing. Our study was not designed to answer whether the association 320 
between Haemophilus spp. and NETs is due to natural selection owing to H. influenzae’s 321 
resistance to NET killing (37).  322 
Branzk et al observed that NET formation in response to Gram-negative bacteria did not 323 
occur under normal conditions, where neutrophil bacterial interaction results in 324 
phagocytosis and intracellular clearance. When phagocytosis was prevented, through a 325 
physical barrier, NET formation resulted (29). We hypothesised therefore that phagocytosis 326 
would be impaired in COPD airway neutrophils to explain the exaggerated NET formation in 327 
COPD. Our data showed a direct relationship between airway neutrophil phagocytosis and 328 
NETs. Experimentally, exposure to soluble sputum from patients with COPD inhibited 329 
phagocytosis in healthy neutrophils and could be replicated using supernatants from healthy 330 
donor neutrophils that had been induced to undergo NETosis by PMA. We speculate that 331 
neutrophil activation and NET formation in COPD may cause the release of mediators that 332 
inhibit phagocytosis, creating an airway environment that promotes NET formation (38, 39). 333 
This may be exacerbated by ICS, which are widely used in COPD, as we demonstrated that 334 
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fluticasone propionate in vitro and in vivo was associated with reduced neutrophil 335 
phagocytosis. 336 
While the question of whether NETs are able to kill bacteria is controversial, it is clear that 337 
NETs are a less effective means of bacterial killing compared to phagocytosis and are 338 
associated with greater collateral damage (36). We speculate that this could explain the loss 339 
of bacterial diversity and increased abundance of Haemophilus spp. OTUs in COPD. Larger, 340 
longitudinal studies are needed to determine whether NET formation identifies a specific 341 
endotype in COPD, whether NET status fluctuates over time and whether loss of phagocytic 342 
ability and subsequent NET formation precedes changes in the lung microbiota. 343 
We acknowledge some potential limitations of the study. The majority of data are cross-344 
sectional and we are unable to assess whether the presence of NETs lead to more rapid 345 
disease progression, such as long term decline in FEV1. We performed a large number of 346 
correlations in this study, increasing the possibility that some of the weaker correlations may 347 
be statistically significant by chance. For this reason and due to relatively small sample sizes 348 
in some of our analyses there is a need for independent replication of our findings. Sputum 349 
was selected for microbiota analysis due to the less invasive method of collection compared 350 
to bronchoalveolar lavage; whilst it is accepted that a protected brush bronchoscopy would 351 
be preferred for monitoring the lower airway microbiota, sputum is more practical in a 352 
routine clinical environment. The results of our study are similar to previously published data 353 
acquired using various sample types from both COPD and healthy lungs as reviewed in 354 
Dickson et al (40). It is not feasible to perform and quantify microscopy images in very large 355 
number of patients and it is unlikely to be translated into a point of care clinical test, 356 
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whereas a NET ELISA, such as those described here, are potentially applicable in clinical 357 
practice. 358 
Simplified in vitro systems do not necessarily reflect the complex lung environment, and so, 359 
although we can demonstrate inhibitory effects of COPD lung fluids and drugs like 360 
fluticasone propionate on neutrophil functions such as phagocytosis, we acknowledge that 361 
such assays are highly simplified. Nevertheless, we have identified a correlation between 362 
reduced phagocytosis ex vivo in airway neutrophils which may be more reflective of their 363 
true in vivo function. 364 
The majority of patients with COPD are treated with ICS and bronchodilators (38). ICS target 365 
eosinophilic inflammation and effectively reduce exacerbations in eosinophilic COPD (38, 366 
41). Patients who do not have eosinophilic COPD have neutrophilic airway inflammation and, 367 
to date, we have limited therapies capable of targeting neutrophilic inflammation (5). Drugs 368 
targeting NETs are in development; inhibition of NET formation has been shown to be 369 
beneficial in experimental models of diverse clinical diseases from psoriasis to lupus (42, 43). 370 
Our data suggests that NETs should be further evaluated as a therapeutic target in COPD. 371 
Conclusions 372 
NETs are associated with disease severity and exacerbation frequency in this COPD cohort. 373 
NETs are associated with microbial dysbiosis and further longitudinal studies are needed to 374 
determine if modulation of NETs may affect airway microbial dysbiosis and clinical 375 
outcomes. 376 
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TABLES 529 
Table 1: Demographic and clinical characteristics of the cohort at study entry. 530 
 Cohort – N(%) or 
mean (StDev) 
Demographics and major comorbidities 
N 99 
Age (StDev) 71.3 (8.3) 
Age at diagnosis (StDev) 59.8 (11.5) 
Male gender (%) 66 (66.7) 
Active smokers (%) 24 (24.2) 
Ex-smokers (%) 71 (71.7) 
Pack years (StDev) 42 (29) 
BMI (StDev) 28.3 (5.7) 
Myocardial Infarction (%) 15 (15.2) 
CABG (%) 14 (14.1) 
Angina (%) 24 (24.2) 
Stroke (%) 9 (9.1) 
Diabetes (%) 19 (19.2) 
Cancer (%) 3 (3.0) 
CCF (%) 5 (5.1) 
Lung surgery (%) 4 (4.0) 
Kidney disease (%) 1 (1.0) 
 
COPD Severity 
% Predicted FEV1 (StDev) 70.3% (21.7) 
MRC Dyspnoea Score (StDev) 2.8 (1.4) 
Exacerbations per year (StDev) 2.1 (2.0) 
GOLD Score  
A (%) 7 (7.1) 
B (%) 36 (36.4) 
C (%) 5 (5.1) 
D (%) 51 (51.5) 
SGRQ (StDev) 44.5 (22.1) 
On LTOT 5 (5.1) 
 
Medications 
Statins (%) 54 (54.6) 
ICS (%) 61 (61.6) 
LABA (%) 13 (13.1) 
LAMA (%) 53 (53.5) 
Theophylline (%) 8 (8.1) 
Mucolytic (%) 13 (13.1) 
Aspirin (%) 26 (26.3) 
Beta Blocker (%) 13 (13.1) 
ACE-inhibitor (%) 27 (27.3) 
ARB (%) 6 (6.1) 
Clopidogrel (%) 8 (8.1) 
Abbreviations: ACE= angiotensin converting enzyme, ARB= angiotensin receptor blocker, 531 
BMI= body mass index, CABG= coronary artery bypass graft, CCF= congestive cardiac failure, 532 
FEV1= forced expiratory volume in 1 second, ICS= inhaled corticosteroid, LABA= long acting 533 
beta agonist, LAMA= long acting muscarinic antagonist, LTOT= long term oxygen therapy, 534 
MRC= Medical Research Council, SGRQ= St. Georges Respiratory Questionnaire, StDev= 535 
standard deviation.  536 
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FIGURE LEGENDS 537 
Figure 1. Histone-elastase complex concentrations in soluble sputum of COPD patients are 538 
associated with clinical markers of COPD disease severity. A: NET concentration in stable 539 
samples compared to GOLD score (n=99). B: NET concentration compared to number of 540 
exacerbations reported by study patients in previous year (n=99). C: NET concentration in 541 
stable samples compared to percent predicted forced expiratory volume in 1 second (% 542 
predicted FEV1) (n=99). D: NET concentration in stable samples compared to COPD 543 
assessment test (CAT) (n=99).  544 
Figure 2. Sputum biomarkers and severity of COPD. A: Sputum myeloperoxidase activity is 545 
associated with GOLD stage and with the frequency of exacerbations (n=99). B: Sputum cell 546 
free DNA (cfDNA) is not significantly associated with GOLD stage or exacerbations (n=99). C: 547 
Neutrophil elastase activity is associated with GOLD stage but not significantly with 548 
frequency of exacerbations (n=99). 549 
Figure 3: Microbiota composition and NET formation in stable COPD.  In the above bar 550 
figure, each bar represents an individual patient. A: Microbiomes of COPD patients when 551 
clinically stable with 14 of the most commonly identified genera per patient highlighted.  552 
Each patient is only represented once. B: Correlation of all stable samples Shannon-Wiener 553 
Diversity Indexes (SWDI) against NET complexes (n=89). C: NET formation in stable soluble 554 
sputum samples stratified by % of Haemophilus spp. OTUs present (n=82). 555 
Figure 4: Changes in microbiota and NET formation at exacerbation of COPD. A: Individual 556 
microbiome profiles of all exacerbation samples (n=37 from 24 separate exacerbation 557 
events) with corresponding start and end exacerbation samples adjacent to each other, 558 
exacerbation number denotes start of exacerbation sample with end of exacerbation sample 559 
positioned to its right.  Some patients were unable to produce sputum at both visits. B: 560 
Examples of longitudinal changes in microbiomes over time, showing two individual patients. 561 
StartEx refers to the onset of exacerbation before treatment, EndEx refers to 10 days 562 
following exacerbation treatment once clinical recovery has occurred. C: Haemophilus spp. 563 
OTU dominance at exacerbation is associated with significantly higher NET formation (n=24). 564 
D: Based on blood eosinophilia (26), NETs were elevated in non-eosinophilic exacerbations 565 
and not in eosinophilic exacerbations (n=24).  566 
Figure 5: Platelet-neutrophil aggregates are present in COPD airways A: Neutrophils were 567 
gated based on CD16 and side scatter (top left), then the quadrants for positive and negative 568 
CD41a set (bottom left) in the isotype control then these gates applied to the test sample 569 
(right panels). The example shows positive staining for the platelet marker CD41a PE. B: No 570 
relationship between DNA-elastase complexes and soluble CD40 ligand, a marker of platelet 571 
activation (n=72). C: No relationship between sputum NETs and CXCL8 in sputum (n=72).  572 
Figure 6: Direct relationship between sputum DNA-elastase complexes and ex vivo 573 
phagocytosis assessed by flow cytometry.  A: Representative image of phagocytosis flow 574 
cytometry showing isotype control (top image) used to set gates for test sample (Bottom 575 
image); test sample results were normalised using isotype control to account for background 576 
fluorescence. B: Phagocytosis of FITC-labelled P. aeruginosa was evaluated by the % of 577 
positive cells and the mean fluorescence (which quantifies the number of fluorescent 578 
bacteria ingested per cell) (n=40).  C: Dose dependent inhibition of phagocytosis of FITC-579 
labelled E. coli by healthy donor neutrophils in response to pre-treatment for 30mins 580 
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fluticasone propionate, pooled soluble sputum (N=7 COPD donors), or supernatant from 581 
neutrophils induced to undergo NETosis by incubation for 4 hours with 20nM PMA. N=4 582 
replicates with different donors for each experiment, (statistical significance p<0.05 is 583 
denoted by *) D: Individual soluble sputum from n=24 patients with COPD used to pre-treat 584 
healthy donor neutrophils followed by phagocytosis of FITC-labelled E. coli for 30 mins.  Data 585 
shows a direct relationship between the sputum DNA-elastase complex concentration and 586 
subsequent neutrophil phagocytosis, suggesting that samples with high NET concentrations 587 
inhibit phagocytosis. 588 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Neutrophil Extracellular Traps are associated with disease severity and microbiota 
diversity in Chronic Obstructive Pulmonary Disease 
Alison J Dicker
1
PhD, Megan L Crichton
1
MFM, Eleanor G Pumphrey
1
, Andrew J Cassidy
1
PhD, 
Guillermo Suarez-Cuartin
2
MD, Oriol Sibila
2
MD, Elizabeth Furrie
1
PhD, Christopher J Fong
1
, 
Wasyla Ibrahim
1
, Gill Brady
1
BSc, Gisli G Einarsson
3
PhD, J Stuart Elborn
3,4
MD, Stuart 
Schembri
1
MD, Sara E Marshall
45
PhD, Colin NA Palmer
1
PhD, James D Chalmers
1
PhD. 
 
1. Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital 
and Medical School, Dundee, Scotland. 
2. Respiratory Department, Hospital de la Santa Creu i Sant Pau, Institut d´Invesitgacio 
Biomedica (IIB) Sant Pau, Barcelona, Spain. 
3. Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical 
Sciences, Queen’s University Belfast, Northern Ireland.  
4. National Heart and Lung Institute, Imperial College London 
5. The Wellcome Trust, 215 Euston Road, London, WN1 2BB 
 
Corresponding Author: Dr James D Chalmers, Division of Molecular and Clinical Medicine, 
University of Dundee, Dundee, DD1 9SY. E-mail: jchalmers@dundee.ac.uk, phone: 01382 
383642 
Contribution: Conception and design: JDC, SEM, SS and CNAP. All authors participated in 
data analysis and interpretation of the data. All authors were involved in writing and 
revising the article prior to submission. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Funding: This study was funded by the Chief Scientist Office, Scotland Grant number 
ETM/262. James D Chalmers acknowledges fellowship support from the Wellcome Trust.  
Sara Marshall is an employee of the Wellcome Trust.  The funding agencies had no other 
role in the preparation, review, or approval of the manuscript. 
 
Conflicts of interest: All authors declare no conflicts of interest in relation to the present 
study.   
Running title: Neutrophil extracellular traps in COPD 
Keywords: Neutrophils, phagocytosis, COPD, Haemophilus, exacerbations 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
METHODS 
Inclusion and Exclusion Criteria 
Patients were included if >40 years; a FEV1/FVC ratio <70% and with a clinical diagnosis of 
COPD.  Exclusion criteria included the inability to give informed consent; previous adverse 
reaction to nebulised hypertonic saline; asthma; bronchiectasis on HRCT scanning; cystic 
fibrosis; active mycobacterial disease; and immunosuppression.  Patients receiving long 
term antibiotic therapy or maintenance oral corticosteroid therapy at screening were also 
excluded; additionally, patients needed to be clinically stable and free of antibiotic or 
corticosteroid therapy for 4 weeks prior to enrolment.   
Data Collection 
All relevant medical history (comorbidities, current medications, significant past conditions, 
operations and diagnostic procedures) was recorded at screening.  Inhaled corticosteroid 
(ICS) dose was converted to Beclomethasone daily dose equivalent for analysis 
Systemic and Airway Inflammation 
Sputum IL-1β, IL-8 and TNFα, Serum CD40L and P-selectin were measured using 
commercially available kits (R&D Systems, Abingdon, UK) according to manufacturers’ 
instructions.  Sputum was processed by ultracentrifugation to obtain soluble sputum as 
previously described (E1).  Soluble sputum was stored at -80°C until analysis.  All sputum 
ELISAs were validated by spike and recovery experiments (E2).  EN-RAGE was measured as 
follows: Plates we coated with 1 in 2000 rabbit polyclonal antibody to EN-RAGE (Abcam 
Ab37657) and washed 3 times with PBS 0.05% tween 20.  Plates were blocked with 1% BSA 
in PBS for 1 hour and then diluted sputum samples or recombinant EN-RAGE standards 
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(diluted in 1% BSA PBS) were added and incubated for 2 hours at room temperature.  Plates 
were incubated with 1ug/ml mouse monoclonal detection antibody (MAB10522, R+D 
systems) in 1% BSA PBS, detected with anti-mouse HRP (R+D systems) and developed with 
TMB substrate with values read at 450nm in a microplate reader. Neutrophil elastase was 
measured using a kinetic assay employing the substrate N-Succinyl-Ala-Ala-Ala-p-
nitroanilide as previously described (Sigma-Aldrich) (E3). Cell free DNA was measured by diluting 
sputum samples 1 In 100 in PBS and adding SYTOX green at a final concentration of 6µM. 
Fluorescence was measured at 538nm emission and 450nm excitation and results were compared to 
a standard curve made from pure DNA of known concentration.  
Fluorescein isothiocyanate (FITC) labelling of bacteria 
Pseudomonas aeruginosa strain PA01 and Escherichia coli strain (ATCC 25922) were grown 
on Pseudomonas isolation agar and nutrient agar plates respectively.  Freshly isolated 
colonies were inoculated into 10mls of Luria-Bertani broth at cultured overnight at 37
o
C 
with gentle shaking.  Cultures were sub cultured 1 in 10 and grown for 3 hours to enter the 
logarithmic growth phase.  Cultures (OD600 = 0.1) were labelled with FITC as described 
below:  Bacterial suspensions were serially diluted and plated out on agar plates to 
determine colony counts.  Overnight cultures of bacteria were heat inactivated 60°C for 1 
hour before centrifugation at 3000 × g for 15 mins and OD brought to 1 with cold PBS.  
Samples were washed with 1% BSA-Hanks’ balanced salt solution (HBSS) containing Ca and 
Mg (Thermo Fisher).  100µL of FITC solution (0.5mg/ml in PBS) was added and the bacteria 
placed on a rotary mixer at 4
o
C for 30 mins.  900µl of ice cold 1%BSA-HBSS was added and 
samples were centrifuged at 10000rpm for 2 minutes, then re-suspended in 1mL 1%BSA-
HBSS.  Labelling was confirmed by flow cytometry and microscopy.  Labelled bacteria were 
stored at -80°C until use. 
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Phagocytosis assays 
Phagocytosis of peripheral blood and airway neutrophils was assessed using a standard flow 
cytometry based assay (E4):  FITC labelled Pseudomonas aeruginosa (strain PA01) and 
Escherichia coli (ATCC 25922) were opsonised with 25% pooled healthy donor serum at 37
o
C 
for 1 hour.  Opsonised bacteria were then added to patient neutrophils at a multiplicity of 
infection 10:1 to neutrophils (0.5 x 10
6
 per experiment).  Phagocytosis was permitted at 
37
o
C for up to 30 mins and then terminated by placing the samples on ice.  Excess bacteria 
were removed by washing with PBS and cells subsequently analysed by flow cytometry.  To 
differentiate phagocytosed (intracellular) bacteria from adherent (extracellular bacteria), 
cells were incubated with 0.1% trypan blue to quench extracellular fluorescence.  A 
minimum of 10,000 events were counted.  Results were expressed as the normalised rate of 
phagocytosis and mean fluorescent intensity for each sample.  For some of these 
experiments, neutrophil phagocytosis was assessed after treatment with COPD patients’ 
soluble sputum (at a final concentration ranging from 10% soluble sputum to 0.01% in PBS), 
supernatant from phorbol 12-myristate 13-acetate (PMA) treated neutrophils or controls 
(PBS or Cytochalasin D) at 37
o
C.   
For analysis of sputum neutrophils, the protocol was modified as follows; whole sputum was 
incubated at room temperature in PBS with 5% normal human serum, centrifuged at 20 x g 
for 10 mins then filtered through 48µM nylon gauze.  1 x 10^6 sputum neutrophils were 
incubated with FITC labelled PA01 bacteria or control for 30 mins at 37°C at a multiplicity of 
infection of 10:1 as described above, washed in PBS and analysed as above. 
Sputum neutrophil platelet aggregates 
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Sputum neutrophil platelet aggregates were measured by flow cytometry.  Sputum 
neutrophils were isolated from sputum as for the phagocytosis assay above, aggregated 
were visualised by co-staining the neutrophils with CD16 and CD41a (BD biosciences), gating 
of the neutrophils based on forward scatter, side scatter and CD16 then the normalised rate 
of platelet binding (CD41a) determined against an isotype control.  A minimum of 10,000 
events were counted. 
Sputum Neutrophil Cytospins 
Sputum neutrophils were isolated from sputum by filtering through a 48µM nylon gauze as 
described above, the concentration of cells in 100µL PBS adjusted to 30,000 cells per 
cytospin. The microscope slides were assembled with filter paper and cytofunnels then pre-
wetted with 50µL PBS by centrifugation at 1000 rpm for 1 min in a cytocentrifuge 
(Shandon). Cells were added to cytofunnel and centrifuged for 1200 rpm for 3 mins. Slides 
were removed, allowed to air dry, stained with DiffQuik, dried, fixed and mounted before 
differential counts were determined. 
NET Assay with purified neutrophils 
NETs were studied using a fluorescent assay (E5) as follows:  In 96 well plates, 5 x 10
4
 
isolated blood neutrophils were added per well in HBSS containing Ca and Mg 
(ThermoFisher) and 20mM Hepes.  After adhering for 30 mins, cells were treated with PMA 
at concentrations 1-100nM to induce NET formation.  In some of these experiments, 
diphenyleneiodonium (DPI), a NADPH oxidase inhibitor that blocks NETosis, was added at 
100nM for 30 mins prior to stimulation with PMA.  After 4 hours at 37°C, NETs were stained 
with SYTOX green (10uM final concentration).  Extracellular DNA was quantified by mean 
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fluorescence and shown to correlate (r
2
 >0.95) with NET quantification by fluorescence 
microscopy (E5). 
Sputum microbiota sample preparation 
DNA and RNA was extracted from whole sputum using the AllPrep DNA/RNA Mini kit on the 
QIAcube automation platform (QIAGEN) as follows:  Whole sputum was incubated in an 
equal volume of 1 in 10 diluted Sputolysin (Calbiochem) in a shaking incubator for 30mins at 
37°C, mixed with Buffer RLT as per the AllPrep kit protocol, then passed through 
QIAshredder columns (QIAGEN) with the resulting supernatant undergoing sequential DNA 
and RNA extraction on the QIAcube.  Quality and quantity of the DNA and RNA was 
determined by Nanodrop and Qubit machine, using the Qubit dsDNA broad range kit 
(Thermo Scientific).  Metagenomic sequencing of the bacterial 16S rRNA gene was 
performed following the protocol in the Illumina library prep guide 
(https://www.illumina.com/content/dam/illumina-
support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-
library-prep-guide-15044223-b.pdf), using primers targeting the V3 and V4 region (E6).  
Nextera XT Indices were added to each sample to allow multiplexing and the libraries 
sequenced using 2 x 300 paired end sequencing on the MiSeq platform using a MiSeq V3 kit 
(Illumina).  Following sequencing on the Illumina MiSeq platform, FastQ files were imported 
into QIIME (version 1.9.0) and quality of reads checked; any reads with a Phred quality score 
less than Q20 were excluded when paired end reads were joined together for each sample. 
Un-joined reads were excluded from subsequent analysis.  Sequences were clustered into 
operational taxonomic units (OTUs) based on 97% sequence similarity using the UCLUST 
algorithm (E7), aligned against the Greengenes Core reference alignment (Version 13.8) (E8) 
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using PyNAST (Version 1.2.2) (E9).  Taxonomy of the OTUs was assigned using the Ribosomal 
Database Project Classifier (Version 2.2) with the de novo OTU picking option (E10).  OTUs 
were filtered to remove singletons and unassigned OTUs, or OTUs identified as Eukaryota, 
Human and Cyanobacteria.  The dataset was normalised to the lowest number of OTUs and 
the Shannon-Wiener Species Diversity Index (SWDI) of the samples determined. All 
sequence data generated in this project can be found on the NCBI Sequence Read Archive, 
accession number SRP073159, a table of OTUs identified is shown in this supplement (Table 
E2). 
Validation of NET assays 
A series of controls were performed to ensure that the assays used in this study were 
measuring NETs. Citrullinated histones are regarded as one of the most specific markers of 
NET formation and their presence is frequently used as evidence that NET formation has 
occurred (E11). We used a semi-quantitative ELISA for citrullinated histone H3 (CITH3) 
(Cayman Chemical) to identify sputum samples with NETs present. Levels of DNA-elastase or 
histone-elastase complexes were compared between samples with detectable CITH3, 
defined as above the lower limit of detection of the ELISA, and those with undetectable 
CITH3 (at 1 in 10).  
To exclude the possibility that sample preparation methods may affect NET formation we 
compared the detection of NETs in samples from patients prepared by ultracentrifugation at 
50,000g for 90 minutes with samples diluted in 4xPBS followed by standard centrifugation, 
and also tested the correlation of samples obtained from paired sputum and BAL from the 
same patient taken on the same day. Agreement was determined by linear regression and 
by the Bland-Altman method.  
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Finally, we investigated possible passive interaction between DNA and elastase or between 
DNA and other components in sputum (E12). Fish sperm DNA (Sigma Aldrich) was mixed 
with purified neutrophil elastase (Sigma Aldrich) at 37
o
C for 1 hour. Neutrophil elastase was 
added at a concentration of 3ug/ml based on the mean concentration of total elastase 
present in 10 sputum samples (measured by ELISA, Total neutrophil elastase, Assaypro 
EE1001-1). Increasing concentrations of DNA were added at 4, 20 and 40ug/ml based on 
concentrations of DNA measured in sputum samples. Passive association was measured by 
DNA-elastase ELISA as described in the main manuscript text. 
To evaluate passive association in vivo, soluble sputum contained 120ng/ml neutrophil 
elastase was incubated at 37
o
C for 1 hour with DNA at 4, 20 and 40ug/ml and the effect of 
increasing excess DNA on the presence of DNA-elastase complexes was measured by ELISA. 
To validate the Histone-elastase assay, we performed a degradation experiment using 
DNAse. If histones and elastase are indirectly associated as part of DNA based traps, then 
the levels of histone-elastase complexes should be reduced by treatment of sputum 
samples with DNAse. Conversely, if histones and elastase were passively associating and 
directly bound, then DNase treatment should have no effect on sputum levels of histone-
elastase complexes. Sputum containing 10ug/ml of DNA was incubated with 0 to 5 units of 
DNAse, where 1 unit is the amount of DNAse required to degrade 1ug of DNA.  
 
Statistical Analysis 
Statistical analysis of data was carried out using SPSS 21 and GraphPad Prism 6.07.  
Multivariable analysis was conducted using logistic regression for categorical outcomes with 
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model fit evaluated with the Hosner-Lemeshow goodness of fit test.  Multiple linear 
regression was used for continuous outcomes and negative binomial models for analysis of 
exacerbations.  Pre-specified confounders were age, gender, smoking status, BMI, FEV1% 
predicted, MRC dyspnoea score and use of inhaled corticosteroids (ICS).  Biomarker method 
agreement was evaluated by linear regression and Bland-Altman plots.  Statistical 
significance was set at P<0.05.  
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RESULTS 
Validation of NET ELISA 
DNA-elastase complexes accurately quantified NETs induced in healthy control neutrophils 
by treatment with PMA whilst release of DNA-elastase complexes was inhibited by 
diphenyleneiodonium (DPI), which prevents NET formation through NADPH oxidase.  
Importantly, neutrophils lysed with 0.1% Triton X100 released negligible quantities of DNA-
elastase complexes (Figure E1A).  There was a direct correlation between the DNA-elastase 
and SYTOX fluorescence in healthy control blood neutrophils treated with PMA (Figure E1B).  
In patient samples, there was a strong correlation between MPO-DNA and DNA-elastase 
ELISAs, and between the DNA-elastase and Histone-elastase ELISAs (Figure E1C, r=0.81, 
p<0.0001 and figure E1D r=0.66, p<0.0001 respectively). Samples containing citrullinated 
histones (N=30) contained more DNA-elastase complexes and histone-elastase complexes 
(p<0.0001 for all comparisons) compared to samples without detectable citrullinated 
histones by ELISA (N=30) (Figures S1E and S1F respectively).  
(FIG E1) 
We found no evidence that sample preparation affected the formation of NETs, with a 
strong linear correlation demonstrated between samples split for ultracentrifugation and 
PBS dilution methods, and between sputum and BAL samples taken from the same patient 
on the same day (Figure E2).  
(FIG E2) 
We found little evidence of non-specific interaction between DNA and elastase. Incubation 
of increasing concentrations of DNA with elastase resulted in only low levels of DNA-
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elastase complexes detectable by ELISA, at levels far below those detected in patients. 
Adding increasing concentrations of free DNA to sputum samples did not result in significant 
increases in DNA-elastase complexes over the levels present prior to addition of DNA (Figure 
E3A). As a specific control for the histone-elastase complex assay, we treated sputum with 
DNAse to determine if this could disrupt NET complexes. We demonstrated a dose 
dependent decrease in histone-elastase complexes with DNAse treatment (p=0.01) (Figure 
E3B).  
(FIG E3) 
NETs are associated with clinical disease severity in stable COPD 
(FIG E4) 
(TABLE E1)  
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Sputum NET concentration is associated with microbiota composition  
(FIG E5) 
 
Impact of antibiotic therapy on diversity and Haemophilus dominance in COPD 
Sequential samples were studied in a subgroup of patients over the 6 month follow-up 
period. 28 patients had paired samples and received no antibiotic therapy between baseline 
and follow-up. 38 patients had paired samples and received at least one course of 
antibiotics between baseline and follow-up. 
Changes between the two time-points in the Shannon-Wiener Species Diversity Index (A), 
Chao index (B) and % of Haemophilus OTU’s (C) are shown in Figure E6. During follow-up, 
mean change in SWDI was 0.93 for those not receiving antibiotics and 0.46 for those 
receiving antibiotics. Mean difference 0.47 95% CI -0.66 to 1.61, p=0.4. The proportion of 
patients experiencing a reduction in SWDI was also not significantly different between 
groups 36% for those not receiving antibiotics vs 50% for those receiving antibiotics, p=0.2.   
(FIG E6) 
 
In terms of the Chao index, mean change during follow-up was -416 for those not receiving 
antibiotics and -157 for those receiving antibiotics (mean difference -258 9% CI -635 to 
117,p=0.2). The proportions showing a reduction in Chao index, were 67% vs 52%, p=0.2.  
There was also no significance difference in Haemophilus OTUs between those treated with 
antibiotics and those not receiving antibiotics. Mean change was -8% for those receiving 
antibiotics and -12% for those not receiving antibiotics (mean difference -4% 9%CI -28 to 20, 
p=0.7).   
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We conclude from this analysis that antibiotic therapy does not have a large impact of 
diversity in the short term, but that our study was not powered to show small short term 
effects and was not designed to show longer term effects with repeated antibiotic courses 
over time. 
In a second longitudinal analysis we compared DNA-elastase and histone-elastase 
complexes measured at baseline and follow-up visits to examine the stability of the marker 
when patients are clinically stable. We observed high variability as shown below in figure E7. 
There were, however, no significant differences between baseline and follow-up for either 
the histone-elastase (pairwise comparison p=0.6) and DNA elastase (p=0.2).  
(FIG E7) 
(FIG E8) 
(TABLE E2)
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Table E1. Comparison of different methods of measuring NET components, NET complexes, 
and cytokines hypothesised as being important in lung inflammation and their association 
with clinical markers of COPD disease severity*p<0.05, **p<0.001, ***p<0.0001. In view of 
multiplicity of testing, all p-values should be interpreted with caution. 
 
  
Assay Age  Exacerbations MRC 
Dyspnoea 
Score  
Long term 
Oxygen 
treatment 
Sputum colour % predicted 
FEV1 
CAT SGRQ GOLD 
score 
Assays specifically 
targeting NETS 
         
Histone-elastase NET 0.13 0.27** 0.20* 0.28** 0.31** -0.31** 0.23** 0.27** 0.30** 
DNA-elastase NET 0.05 0.28** 0.27*** 0.19* 0.25** -0.30** 0.33*** 0.37*** 0.31*** 
Non-specific NET 
components 
         
cfDNA 0.06 0.12 0.07 0.17* 0.41*** -0.15 0.06 0.14 0.14 
Elastase activity 
kinetic 
0.11 0.23* 0.05 0.10 0.39*** -0.20* 0.15 0.19* 0.21* 
MPO activity -0.03 0.21** 0.02 0.17 0.43*** -0.11 0.06 0.12 0.16* 
EN-RAGE 0.03 0.08 0.11 0.09 0.11 -0.26** 0.21** 0.27*** 0.23** 
Cytokines          
IL-1beta 0.14* 0.09 0.02 0.18* 0.37*** -0.14 0.10 0.14 0.19** 
CXCL8 0.10 0.03 0.04 0.05 0.39*** -0.14 0.14 0.16 0.20** 
TNF-alpha 0.10 0.15 0.07 0.28** 0.40*** -0.15 0.13 0.15 0.20** 
Cells          
Neutrophil cell count 0.18 0.06 0.25* 0.18 0.30** -0.13 0.08 0.13 0.16 
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Table E2: List of OTUs identified in stable and exacerbating COPD sputum samples, classified 
at the genus level. If identification was not possible at genus level, the OTUs were classified 
at a higher taxonomic level. OTUs identified in less than 10 samples and with a maximum 
representation in a sample of 0.5% are excluded from this list.  
Stable OTUs Exacerbation OTUs 
[Prevotella] [Prevotella] 
Acholeplasma Achromobacter 
Achromobacter Acinetobacter 
Acidocella Actinobacillus 
Acinetobacter Actinomyces 
Actinobacillus Aggregatibacter 
Actinomyces Agrobacterium 
Aeromocrobium Anaerococcus 
Aggregatibacter Arsenicicoccus 
Agrobacterium Atopobium 
Alloiococcus Bacillus 
Anaerococcus Bacteroides 
Anaerovorax Bifidobacterium 
Atopobium Bulleidia 
Bacillus Burkholderia 
Bacteroides Butyrivibrio 
Beijerinckia Campylobacter 
Bifidobacterium Capnocytophaga 
Bilophila Cardiobacterium 
Bradyrhizobium Carnobacterium 
Bulleidia Catonella 
Burkholderia Chryseobacterium 
Butyrivibrio Corynebacterium 
Campylobacter Cryocola 
Capnocytophaga Curvibacter 
Cardiobacterium Delftia 
Catonella Dermacoccus 
Chryseobacterium Devosia 
Chthonomonas Dialister 
Clostridium Dokdonella 
Comamonas Eikenella 
Corynebacterium Elizabethkingia 
Curvibacter Enhydrobacter 
Delftia Enterococcus 
Desulfobulbus Ethanoligenens 
Desulfovibrio Filifactor 
Devosia Finegoldia 
Dialister Fusobacterium 
Dokdonella Gemella 
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Eikenella Granulicatella 
Elizabethkingia Haemophilus 
Enhydrobacter Kingella 
Erwinia Klebsiella 
Exiguobacterium Kocuria 
Filifactor Lactobacillus 
Finegoldia Lactococcus 
Flavisolibacter Lautropia 
Fluviicola Leptotrichia 
Fusobacterium Megasphaera 
Gemella Methylobacterium 
Gemmata Microbacterium 
Geobacillus Micrococcus 
Granulicatella Mogibacterium 
Haemophilus Moraxella 
Hymenobacter Moryella 
Jonquetella Mycoplasma 
Kaistobacter Neisseria 
Kingella Nevskia 
Lactobacillus Novosphingobium 
Lactococcus Ochrobactrum 
Lautropia Oribacterium 
Leptotrichia Paludibacter 
Lysinibacillus Parachlamydia 
Megasphaera Paracoccus 
Methylobacterium Parvimonas 
Microbacterium Pasteurella 
Mogibacterium Pedobacter 
Moraxella Peptococcus 
Moryella Peptoniphilus 
Mycobacterium Peptostreptococcus 
Mycoplasma Phyllobacterium 
Neisseria Porphyromonas 
Ochrobactrum Prevotella 
Oribacterium Propionibacterium 
Paenibacillus Pseudomonas 
Paludibacter Pseudoramibacter_Eubacterium 
Parachlamydia Psychrobacter 
Paracoccus Ralstonia 
Parvimonas Rhodococcus 
Pasteurella Rothia 
Pedobacter Ruminococcus 
Peptococcus Schwartzia 
Peptoniphilus Selenomonas 
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Peptostreptococcus Slackia 
Phyllobacterium Sneathia 
Porphyromonas Sphaerochaeta 
Prevotella Sphingobacterium 
Propionibacterium Sphingomonas 
Propionivibrio Staphylococcus 
Proteus Stenotrophomonas 
Pseudomonas Streptococcus 
Pseudoramibacter_Eubacterium Tannerella 
Pyramidobacter Thermus 
Ralstonia Treponema 
Rheinheimera Unknown [Mogibacteriaceae] 
Rhodococcus Unknown [Mogibacteriaceae] 
Roseateles Unknown [Paraprevotellaceae 
Roseburia Unknown Acetobacteraceae 
Rothia Unknown Actinomycetaceae 
Scardovia Unknown Aerococcaceae 
Schwartzia Unknown Aeromonadaceae 
Segetibacter Unknown Alphaproteobacteria 
Selenomonas Unknown Bacilli 
Sharpea Unknown Bacteria CW040 
Slackia Unknown Bacteria EW055 
Sneathia Unknown Bacteria F16 
Sphaerochaeta Unknown Bacteria Rs-0445 
Sphingobacterium Unknown Bacteria SR1 
Sphingomonas Unknown Bacteria TM7-3 
Sphingopyxis Unknown Bacteria WPS-2 
Spirosoma Unknown Bacteroidales 
Staphylococcus Unknown Bacteroidales S24-7 
Stenotrophomonas Unknown Bifidobacteriaceae 
Streptococcus Unknown Bradyrhizobiaceae 
Sutterella Unknown Cardiobacteriaceae 
Tannerella Unknown Caulobacteraceae 
Treponema Unknown Chitinophagaceae 
Unknown [Chloracidobacteria] DS-
100 Unknown Clostridiales 
Unknown [Chloracidobacteria] 
Ellin6075 Unknown Clostridiales 
Unknown [Chloracidobacteria] RB41 Unknown Comamonadaceae 
Unknown [Mogibacteriaceae] Unknown Coriobacteriaceae 
Unknown [Paraprevotellaceae] Unknown Dethiosulfovibrionaceae 
Unknown [Tissierellaceae] Unknown Enterobacteriaceae 
Unknown [Weeksellaceae] Unknown Flavobacteriaceae 
Unknown Acetobacteraceae Unknown Gemellaceae 
Unknown Acidimicrobiales C111 Unknown Gemellaceae 
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Unknown Acidobacteria Unknown Intrasporangiaceae 
Unknown Actinomycetaceae Unknown Lachnospiraceae 
Unknown Actinomycetales Unknown Lachnospiraceae 
Unknown Aerococcaceae Unknown Lactobacillales 
Unknown Alcaligenaceae Unknown Moraxellaceae 
Unknown Alphaproteobacteria Unknown Neisseriaceae 
Unknown Anaerolinaceae SHD-231 Unknown Oxalobacteraceae 
Unknown Aurantimonadaceae Unknown Oxalobacteraceae 
Unknown Bacilli Unknown Pasteurellaceae 
Unknown Bacteria BD1-5 Unknown Peptococcaceae 
Unknown Bacteria CW040 Unknown Peptostreptococcacea 
Unknown Bacteria EW055 Unknown Phycisphaerales 
Unknown Bacteria F16 Unknown Propionibacteriaceae 
Unknown Bacteria Rs-045 Unknown Rickettsiales 
Unknown Bacteria SR1 Unknown Rickettsiales 
Unknown Bacteria TM7-3 Unknown Solirubrobacteraceae 
Unknown Bacteroidales Unknown Streptococcaceae 
Unknown Bacteroidales BE24 Unknown Veillonellaceae 
Unknown Bacteroidales S24-7 Unknown Vibrionaceae 
Unknown Bifidobacteriaceae Unknown Weeksellaceae 
Unknown Caldilineaceae Unknown Xanthomonadaceae 
Unknown Campylobacterales Unknown Xanthomonadaceae 
Unknown Caulobacteraceae Unkown Bacteria BD1-5 
Unknown Chitinophagaceae Variovorax 
Unknown Clostridiales Veillonella 
Unknown Clostridiales 
Unknown Comamonadaceae 
Unknown Coriabacteriaceae 
Unknown Dethiosulfovibrionaceae 
Unknown Enterobacteriaceae 
Unknown Enterobacteriaceae 
Unknown Firmicutes 
Unknown Flavobacteriaceae 
Unknown Gaiellaceae 
Unknown Gaiellales 
Unknown Gaiellales AK1AB1_02E 
Unknown Gemellaceae 
Unknown Geodermatophilaceae 
Unknown Intrasporangiaceae 
Unknown Koribacteraceae 
Unknown Lachnocpiraceae 
Unknown Lactobacillaceae 
Unknown Lactobacillales 
Unknown Leptotrichiaceae 
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Unknown Methylobacteriaceae 
Unknown Microbacteriaceae 
Unknown Microbacteriaceae 
Unknown Micrococcaceae 
Unknown Moraxellaceae 
Unknown Myxococcales OM27 
Unknown Nacillaceae 
Unknown Neisseriaceae 
Unknown Neisseriaceae 
Unknown Nocardioidaceae 
Unknown Oxalobacteraceae 
Unknown Oxalobacteraceae 
Unknown Paenibacillaceae 
Unknown Pasteurellaceae 
Unknown Pasteurellaceae 
Unknown Peptostreptococcaceae 
Unknown Phycisphaerae WD2101 
Unknown Phyllobacteriaceae 
Unknown Planococcaceae 
Unknown Prevotellaceae 
Unknown Propionibacteriaceae 
Unknown Pseudomonadaceae 
Unknown Rhizobiaceae 
Unknown Rhodobiaceae 
Unknown Rickettsiaceae 
Unknown Rickettsiales 
Unknown Rickettsiales 
Unknown Rikenekkaceae Blvii28 
Unknown Ruminococcaceae 
Unknown Sinobacteraceae 
Unknown Solibacterales 
Unknown Solirubrobacteraceae 
Unknown Solirubrobacterales 
Unknown Solirubrobacterales 
Unknown Sphingomonadaceae 
Unknown Sporichthyaceae 
Unknown Tenericutes ML615J-28 
Unknown Thermomicrobia JG30-KF-CM45 
Unknown Veillonellaceae 
Unknown Veillonellaceae 
Unknown Verrucomicrobiaceae 
Unknown Xanthomonadaceae 
Veillonella 
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FIGURE LEGENDS 
 
Figure E1. Validation of an ELISA to measure neutrophil extracellular trap (NET) formation 
through detection of DNA-elastase and histone-elastase complexes. A: Quantification of 
NETs in neutrophils induced by phorbol 12-myristate 13-acetate and inhibited by 
diphenyleneiodonium (values shown are the mean and SEM of 3 independent experiments). 
B:  Correlation of DNA-elastase complexes with SYTOX green quantification of extracellular 
DNA after neutrophils were induced to undergo NET formation with PMA, both of which are 
accepted proxies for NETs (n=7 samples). C and D: Correlation of DNA-elastase complexes 
with Histone-elastase complexes (n=162 samples) and MPO-DNA complexes (n=82 samples). 
E and F: citrullinated histone H3 positive samples contain DNA-elastase and Histone-elastase 
complexes, indicative of NET formation.  
Figure E2:  NETs are not induced due to sample preparation method. A: Correlation 
between different sputum samples methods. B: Bland Altman plots show acceptable 
agreement between sputum samples from the same patient prepared using 
ultracentrifugation and PBS dilution methods. C: Agreement between ultracentrifuged 
sputum and BAL. D: Bland Altman comparison between sputum and BAL in the same 
patient. Data are presented for the DNA-elastase assay. n=10 patient samples per 
comparison.   
Figure E3: A: Limited evidence of passive interaction between DNA and elastase. B: DNAse 
treatment reduces the association between histone and elastase consistent with these 
being contained within NETs. Experiments shown are the mean (standard error of the mean) 
of 3 independent experiments.  
Figure E4. DNA-elastase concentrations in soluble sputum of COPD patients are associated 
with clinical markers of COPD disease severity. A: NET concentration in stable samples 
compared to GOLD score (n=99). B: NET concentration compared to number of 
exacerbations reported by study patients in previous year (n=99). (SGRQ) (n=99). C: NET 
concentration in stable samples compared to percent predicted forced expiratory volume in 
1 second (% predicted FEV1). D: NET concentration in stable samples compared to COPD 
assessment test (CAT) (n=99).  
Figure E5: Two distinct clusters of sputum samples are apparent; the arbitrary cut-off of 
40% Haemophilus spp. OTUs was chosen based on this data.   
Figure E6: Impact of antibiotic therapy during the study on diversity A: Shannon Wiener 
Diversity Index. B: Chao evenness index. C: % Haemophilus spp OTUs. 
Figure E7. Changes over time in levels of NET complexes.  
Figure E8. Relationship between neutrophil assays and phagocytosis. The top 2 panels show 
Histone-elastase complexes, the middle panels caspase positive cells on flow cytometry, and 
the bottom panels cfDNA concentrations in sputum.  
Figure E9. Relationship between inhaled corticosteroid regime and NET formation (P=0.01 
by Kruskal Wallis test).  45% of study participants were receiving fluticasone, 6% budesonide 
containing regimes and 13% beclomethasone contained regimes. 
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